Aflibercept sustained release - Regeneron/Ocular Therapeutix

Drug Profile

Aflibercept sustained release - Regeneron/Ocular Therapeutix

Alternative Names: Aflibercept punctal plug - Regeneron/Ocular Therapeutix; OTX IVT

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ocular Therapeutix; Regeneron Pharmaceuticals
  • Class Antineoplastics; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 23 Oct 2017 Preclinical trials in Diabetic macular oedema in USA before October 2017 (Intravitreous) (Ocular Therapeutix pipeline, October 2017)
  • 13 Oct 2016 Regeneron and Ocular Therapeutix collaborate on the development of Aflibercept sustained release and other therapeutics for Retinal disorders
  • 13 Oct 2016 Preclinical trials in Retinal vein occlusion in USA (Intravitreous) (Ocular Therapeutix pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top